[1]鲁雪红, 张源, 刘文亚. 多排螺旋CT三期增强与3.0T MR多期动态增强扫描诊断肝细胞癌的价值分析. 实用肝脏病杂志, 2018,21(5):749-752. [2]Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology, 2018, 289(3):816-830. [3]Lee S, Kim SS, Roh YH, et al. Diagnostic performance of CT/MRI liver imaging reporting and data system v2017 for hepatocellular carcinoma: a systematic review and meta-analysis. Liver Int, 2020, 40(6):1488-1497. [4]石莹莹, 王元喜. 应用肝脏影像报告与数据管理系统诊断肝细胞癌的价值研究. 实用肝脏病杂志, 2020, 23(1):98-101. [5]罗利红, 胡洁, 周启. LI-RADS超声分类诊断肝脏占位性病变准确性分析. 实用肝脏病杂志, 2020, 23(5):731-734. [6]Corwin MT, Fananapazir G, Jin M, et al. Differences in liver imaging and reporting data system categorization between MRI and CT. Am J Roentgenol, 2016, 206(2):307-312. [7]Zhang YD, Zhu FP, Xu X, et al. Liver imaging reporting and data system: substantial discordance between CT and MR for imaging class identification of hepatic nodules. Acad Radiol, 2016, 23(3):344-352. [8]高德军, 陈耀康, 罗鹰, 等. 3.0T MR-LAVA序列多期动态增强扫描对肝硬化结节病变定性诊断的临床价值研究. 实用肝脏病杂志, 2019, 22(3):393-396. [9]Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol, 2014, 109(9):1328-1348. [10] Lee SM, Lee JM, Ahn SJ, et al. LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology, 2019, 292(3):655-663. [11] Park HJ, Kim YK, Cha DI, et al. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category. Clin Radiol, 2020, 75(6):413-478. [12] Basha MAA, Alazzazy MZ, Ahmed AF, et al. Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? a prospective comparative study. Eur Radiol, 2018, 28(6):2592-2603. [13] Chernyak V, Flusberg M, Law A, et al. Liver imaging reporting and data system: discordance between computed tomography and gadoxetate-enhanced magnetic resonance imaging for detection of hepatocellular carcinoma major features. J Comput Assist Tomogr, 2018, 42(1):155-161. [14] Kim DH, Choi SH, Park SH, et al. Meta-analysis of the accuracy of liver imaging reporting and data system category 4 or 5 for diagnosing hepatocellular carcinoma. Gut, 2019, 68(9):1719-1721. [15] Joo I, Lee JM, Lee DH, et al. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging, 2017,45(3):731-740. [16] Darnell A, Forner A, Rimola J, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology, 2015, 275(3):698-707. [17] Cha DI, Jang KM, Kim SH, et al. Liver imaging reporting and data system on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging. Eur Radiol, 2017, 27(10):4394-4405. [18] 杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究. 实用肝脏病杂志, 2019, 22(4):577-580. [19] Kang JH, Choi SH, Byun JH, et al. Ancillary features in the liver imaging reporting and data system: how to improve diagnosis of hepatocellular carcinoma ≤3cm on magnetic resonance imaging. Eur Radiol, 2020, 30(5):2881-2889. [20] Cannella R, Vernuccio F, Sagreiya H, et al. Liver imaging reporting and data system (LI-RADS)v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations≥10mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinom. Eur Radiol, 2020, 30(7):3770-3781. |